BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. J Clin Oncol 2018;36:1225-31. [PMID: 29522361 DOI: 10.1200/JCO.2017.74.6917] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Lv M, Mao Y, Ma T, Wang Y, Liu X, Song Y, Wang H. Real-World Efficacy of Fulvestrant Monotherapy as the First Treatment or Maintenance Treatment in Patients with Metastatic Breast Cancer. Breast Care (Basel) 2021;16:368-75. [PMID: 34602942 DOI: 10.1159/000510061] [Reference Citation Analysis]
2 Yamamoto S, Kamei S, Tomita K, Fujita C, Endo K, Hiraiwa S, Hasebe T. CT-guided bone biopsy using electron density maps from dual-energy CT. Radiol Case Rep 2021;16:2343-6. [PMID: 34306278 DOI: 10.1016/j.radcr.2021.06.009] [Reference Citation Analysis]
3 Bertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Pérol D, Jaffré A, Goncalves A, Lebitasy MP, D'Hondt V, Dalenc F, Ferrero JM, Levy C, Dabakuyo S, Rouzier R, Penault-Llorca F, Uwer L, Eymard JC, Breton M, Chevrot M, Thureau S, Petit T, Simon G, Frénel JS. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Ther Adv Med Oncol 2021;13:1758835920987657. [PMID: 33613700 DOI: 10.1177/1758835920987657] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Pfeiler G, Gnant M. More is not always better-what can be learned from the D-CARE trial. Ann Transl Med 2020;8:1034. [PMID: 32953834 DOI: 10.21037/atm.2020.04.31] [Reference Citation Analysis]
5 Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med 2020;9:1025-32. [PMID: 31849202 DOI: 10.1002/cam4.2780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
6 Ulaner GA, Saura C, Piha-Paul SA, Mayer I, Quinn D, Jhaveri K, Stone B, Shahin S, Mann G, Dujka M, Bryce R, Meric-Bernstam F, Solit DB, Hyman DM. Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clin Cancer Res 2019;25:7381-7. [PMID: 31548342 DOI: 10.1158/1078-0432.CCR-19-1658] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]